Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.
The bill amends the Fentanyl Sanctions Act to expand its scope from fentanyl and related opioids to a broader category of illicit drugs, and to explicitly include counterfeit drugs and “copy‑cat” active pharmaceutical ingredients in the definitions of illicit trafficking. It adds a statutory definition for “copy‑cat ingredient” (an ingredient intended to mimic an approved or licensed drug substance but manufactured by a different process or with lower purity/quality) and incorporates the FD&C Act definition of “counterfeit drug.” The bill also makes technical and conforming edits throughout the Act (changing terminology from "opioid" to "illicit drug" in many places), authorizes the Director of National Intelligence to use a designee for certain duties and briefings, revises provisions on the use of intelligence resources, and preserves a waiver for access to prescription medications on the HHS drug shortage list.
Scope and definitions: Liberals and centrists worry the "copy‑cat ingredient" language could unintentionally include legitimate generics/biosimilars; conservatives emphasize using the tool aggressively against bad actors.
Relative to its intended legislative type, this bill primarily effects substantive policy change by amending the Fentanyl Sanctions Act to broaden covered items (counterfeit drugs and copy‑cat ingredients), permit DNI delegation, and make technical conforming edits; it is legislative in form and integrates directly with existing law.
The bill amends the Fentanyl Sanctions Act to expand its scope from fentanyl and related opioids to a broader category of illicit drugs, and to explicitly include counterfeit drugs and “copy‑cat” active pharmaceutical ingredients in the definitions of illicit trafficking.
It adds a statutory definition for “copy‑cat ingredient” (an ingredient intended to mimic an approved or licensed drug substance but manufactured by a different process or with lower purity/quality) and incorporates the FD&C Act definition of “counterfeit drug.” The bill also makes technical and conforming edits throughout the Act (changing terminology from "opioid" to "illicit drug" in many places), authorizes the Director of National Intelligence to use a designee for certain duties and briefings, revises provisions on the use of intelligence resources, and preserves a waiver for access to prescription medications on the HHS drug shortage list.
Several sections are purely technical/conforming amendments to align language across statutes.
The bill is a narrowly focused set of statutory and definitional amendments aimed at expanding sanctions coverage to counterfeit and copy‑cat pharmaceutical ingredients and clarifying delegation and reporting mechanics. Those features make it more likely to attract support than a large‑scale fiscal or regulatory package. However, potential controversy about effects on legitimate pharmaceutical trade, extraterritorial sanctions use, and the absence of compromise provisions (sunset/carveouts) introduce obstacles, particularly in the Senate where procedural barriers and stakeholder scrutiny are common.
Relative to its intended legislative type, this bill primarily effects substantive policy change by amending the Fentanyl Sanctions Act to broaden covered items (counterfeit drugs and copy‑cat ingredients), permit DNI delegation, and make technical conforming edits; it is legislative in form and integrates directly with existing law.
Scope and definitions: Liberals and centrists worry the "copy‑cat ingredient" language could unintentionally include legitimate generics/biosimilars; conservatives emphasize using the tool aggressively against bad actors.
These are examples from the analysis, not a ranked list of the most-affected groups.
Scope and definitions: Liberals and centrists worry the "copy‑cat ingredient" language could unintentionally include legitimate generics/biosimilars; conservatives emphasize using the tool aggressively against bad actor…
A mainstream liberal would likely view the bill positively in its intent to protect public health by targeting counterfeit pharmaceutical products that can harm patients.
They would welcome language that recognizes counterfeit drugs and harmful active ingredients as national security and public-health threats, while also wanting strong safeguards for civil liberties, due process, and for legitimate access to medicines.
They would be cautious about ambiguous language (for example the “copy‑cat” definition) that could be used to interfere with lawful generics or biosimilars or to justify broad sanctions without clear evidentiary standards.
A pragmatic centrist would generally welcome a bill that closes an evident gap—explicitly addressing counterfeit drugs and dangerous copy‑cat ingredients—while balancing national security and public health.
They would appreciate technical fixes and broadened scope against illicit drug trafficking, but would seek specificity about how intelligence will be used, what evidentiary standards apply, and how the bill avoids harming legitimate pharmaceutical trade or creating shortages.
They would favor modest, targeted tools with accountability, and want assurances that sanctions are narrowly tailored and coordinated with health regulators.
A mainstream conservative would likely support stronger tools to pressure foreign actors who produce counterfeit drugs and illicit active ingredients, viewing this as an extension of sanctions and law‑enforcement against transnational criminal activity.
They would favor broadened terminology (from "opioid" to "illicit drug") and delegation authority for the DNI as pragmatic steps to improve responsiveness.
They may have some concerns about regulatory overreach if the law inadvertently ensnares legitimate foreign manufacturers, but overall would expect a tough stance on actors enabling counterfeit lethal drugs to be appropriate.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
The bill is a narrowly focused set of statutory and definitional amendments aimed at expanding sanctions coverage to counterfeit and copy‑cat pharmaceutical ingredients and clarifying delegation and reporting mechanics. Those features make it more likely to attract support than a large‑scale fiscal or regulatory package. However, potential controversy about effects on legitimate pharmaceutical trade, extraterritorial sanctions use, and the absence of compromise provisions (sunset/carveouts) introduce obstacles, particularly in the Senate where procedural barriers and stakeholder scrutiny are common.
The bill has not accumulated any surfaced votes yet.
Scope and definitions: Liberals and centrists worry the "copy‑cat ingredient" language could unintentionally include legitimate generics/bi…
The bill is a narrowly focused set of statutory and definitional amendments aimed at expanding sanctions coverage to counterfeit and copy‑c…
Relative to its intended legislative type, this bill primarily effects substantive policy change by amending the Fentanyl Sanctions Act to broaden covered items (counterfeit drugs and copy‑cat ingredients), permit DNI d…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.